Last reviewed · How we verify
RG1662
At a glance
| Generic name | RG1662 |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS) (PHASE2)
- A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
- Basmisanil Positron Emission Tomography Study in Japanese Volunteers (PHASE1)
- A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers (PHASE1)
- Comparative Bioavailability Study of Film-coated Tablet and Granule Formulations of RG1662 (PHASE1)
- A Study of the Effect of RG1662 on Metformin in Healthy Volunteers (PHASE1)
- A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects (PHASE1)
- A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RG1662 CI brief — competitive landscape report
- RG1662 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI